On the other hand, evidence has shown colorectal cancer cells possessing disrupted MLH1 and MSH6 confer similar sensitivity to oxaliplatin as wild-type cells (Fink et al., 1997a; Vaisman et al., 1998). This evidence concerns the gene MSH6 and colorectal cancer.